Diligence memo · auto-generated · as of July 2, 2026
Petra Pharma Corp
Petra Pharma Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Petra Pharma Corp operates in Biotechnology, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Petra Pharma Corp has raised $59M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $31M on 2015-12-23.
Most recent recorded round closed around 2018-08-30.
Valuation (modeled)modeled
Provath models Petra Pharma Corp at approximately $1.1B (range $55M–$4.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.38× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era. Within the normal band (138% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 7.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 84% of Biotechnology peers (4293 compared).
Modeled value ranks above 90% of those peers.
Closest niche peers: Liquid BioScience, Inc., Amphivena Therapeutics, Inc., Tracon Pharmaceuticals, Inc., Tetra Discovery Partners, Inc., ECM Therapeutics, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.